Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of medical composition in preparing medicine for treating xerophthalmia

A composition and dry eye technology, applied in the direction of medical preparations containing active ingredients, drug combinations, pharmaceutical formulas, etc., can solve problems such as premature cataract, side effects, glaucoma, etc.

Inactive Publication Date: 2021-09-03
张腾龙
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, about 5% of the population has a strong reaction to steroid eye drops, which can easily lead to increased intraocular pressure and cause glaucoma
In addition, long-term use also has the risk of premature cataract
[0010] Therefore, it can be seen from the above that although there are existing drugs that can treat dry eye syndrome, there are still certain side effects. In terms of eye-related diseases, prevention is often better than cure. to get the active ingredients you need to prevent eye disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medical composition in preparing medicine for treating xerophthalmia
  • Application of medical composition in preparing medicine for treating xerophthalmia
  • Application of medical composition in preparing medicine for treating xerophthalmia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The composition of embodiment 1 pharmaceutical composition

[0033] First, the composition ratio of the medicinal composition is 37.5% of the wolfberry powder, 31.25% of the chrysanthemum powder, 2.5% of the blueberry powder, 2.5% of the grape seed powder, 0.25% of the zinc gluconate, 0.25% of the yeast selenium, The vitamin A contains 0.03%, the marigold powder 0.025% and the bitter tea oil are formulated according to the above ratio.

[0034] Preparation of wolfberry fruit powder (also chrysanthemum powder or blueberry powder or grape seed powder or marigold powder)

[0035] The wolfberry (also the chrysanthemum or the blueberry or the grape seed or the marigold) is dried and left to stand, and after cooling to room temperature, the wolfberry (also the chrysanthemum or the blueberry or the grape seed or the marigold) is pulverized to obtain wolfberry powder (also chrysanthemum powder or blueberry powder or grape seed powder or marigold powder).

[0036] The acquisit...

experiment example

[0044] Animal grouping and tube feeding

[0045] The present invention uses six-week-old ICR female mice as experimental animals, and divides ICR female mice into five groups. The grouping methods and experimental methods are as follows:

[0046] Please also refer to Figure 1A, which is a schematic diagram of tear volume according to an embodiment of the present invention, and Figure 1B, which is a schematic diagram of tear volume corresponding to different experimental conditions of eye axis distance according to an embodiment of the present invention, as shown in the figure In the figure, Blank is the above-mentioned normal control group, Damage is the injury control group, Oil+DoseL is the drug control group for dry eye syndrome using low doses of the pharmaceutical composition, and Oil+Dose H is the control group in the figure A drug control group for dry eye syndrome using high doses of the pharmaceutical composition, and AFT is a control group for using artificial tears....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a medical composition in preparing a medicine for treating xerophthalmia. Traditional western medicines are replaced by natural substances such as fructus lycii powder, chrysanthemum powder, blueberry powder, grape seed powder, camellia oil, zinc gluconate, selenium yeast, vitamin A and marigold powder, so that the tear amount of eyes is increased, the tear break up time of the eyes is prolonged, and the symptom of the xerophthalmia is relieved.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, especially the use of a pharmaceutical composition for preparing medicine for treating dry eye. Background technique [0002] The eye is the organ of vision, responsible for receiving light from the environment and producing vision. In the process of vision formation, light first passes through the transparent cornea and crystalline lens in the eye. With the concentrating function of these two structures, the light will focus on the retina to form an image, and stimulate the photoreceptor cells in the retina to convert light stimulation into electrical signals. Signal, through the conduction of the optic nerve, the electrical signal reaches the visual area of ​​the brain, and the vision is formed under the signal processing of the nerve cells there. [0003] However, with the rapid development of today's technology, in addition to the rapid mass production of 3C products (mobile phones, ta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/87A61P27/02A61K31/07A61K33/04A61K33/30A61K31/315
CPCA61K36/815A61K36/287A61K36/45A61K36/87A61K36/638A61K33/30A61K36/064A61K33/04A61K31/07A61K36/28A61P27/02A61K31/047A61K31/352A61K36/185A61K2300/00
Inventor 张腾龙
Owner 张腾龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com